Jefferies Financial Group Inc. Acquires 32,385 Shares of Harmony Biosciences Holdings, Inc. $HRMY

Jefferies Financial Group Inc. grew its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 19.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 202,955 shares of the company’s stock after buying an additional 32,385 shares during the period. Jefferies Financial Group Inc.’s holdings in Harmony Biosciences were worth $5,593,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Parkside Financial Bank & Trust lifted its stake in Harmony Biosciences by 4,185.2% in the second quarter. Parkside Financial Bank & Trust now owns 1,157 shares of the company’s stock worth $37,000 after acquiring an additional 1,130 shares during the period. Tower Research Capital LLC TRC increased its position in Harmony Biosciences by 338.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,511 shares of the company’s stock valued at $111,000 after purchasing an additional 2,711 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new position in Harmony Biosciences in the 2nd quarter worth $120,000. Ameritas Investment Partners Inc. raised its holdings in Harmony Biosciences by 12.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,466 shares of the company’s stock worth $141,000 after purchasing an additional 479 shares in the last quarter. Finally, EMC Capital Management purchased a new stake in shares of Harmony Biosciences in the 2nd quarter worth about $195,000. Institutional investors own 86.23% of the company’s stock.

Insider Transactions at Harmony Biosciences

In other Harmony Biosciences news, CEO Jeffrey M. Dayno sold 25,933 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $40.11, for a total transaction of $1,040,172.63. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Sandip Kapadia sold 3,746 shares of Harmony Biosciences stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $37.15, for a total transaction of $139,163.90. Following the transaction, the chief financial officer owned 24,521 shares of the company’s stock, valued at $910,955.15. The trade was a 13.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 50,640 shares of company stock worth $1,932,256. Corporate insiders own 23.60% of the company’s stock.

Harmony Biosciences Stock Performance

Shares of HRMY stock opened at $28.57 on Tuesday. The company’s fifty day moving average price is $34.82 and its 200-day moving average price is $33.70. The stock has a market cap of $1.65 billion, a PE ratio of 10.54, a price-to-earnings-growth ratio of 0.38 and a beta of 0.88. The company has a current ratio of 3.60, a quick ratio of 3.58 and a debt-to-equity ratio of 0.17. Harmony Biosciences Holdings, Inc. has a 12 month low of $25.52 and a 12 month high of $40.87.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $0.38 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.84 by ($0.46). Harmony Biosciences had a return on equity of 19.86% and a net margin of 18.29%.The business had revenue of $243.78 million during the quarter, compared to the consensus estimate of $240.04 million. During the same quarter in the previous year, the business earned $0.85 earnings per share. The firm’s revenue was up 21.1% compared to the same quarter last year. On average, equities analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HRMY has been the topic of a number of research reports. Mizuho set a $50.00 target price on shares of Harmony Biosciences in a research note on Thursday, February 19th. Needham & Company LLC decreased their price target on shares of Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating for the company in a research note on Wednesday, February 25th. Zacks Research lowered shares of Harmony Biosciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Bank of America cut their price objective on Harmony Biosciences from $32.00 to $28.00 and set an “underperform” rating on the stock in a research report on Wednesday, February 25th. Finally, HC Wainwright reiterated a “buy” rating and set a $55.00 target price on shares of Harmony Biosciences in a report on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $42.67.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc is a commercial?stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.